

# PANCREATIC CANCER

## HIGHLIGHTS MARSEILLE, FIGHT CANCER

LE PHARO | MARSEILLE FRANCE  
2020 JANUARY 16-17



### I PROGRAMME

#### AN EVENT ORGANISED BY PAOLI-CALMETTES INSTITUTE

##### PRESIDENTS

Pr Jean Robert Delpero (France)  
Pr Patrice Viens (France)

##### SCIENTIFIC COMMITTEE

Jacques Ewald (France)  
Marine Gilabert (France)  
Marc Giovannini (France)  
Juan Iovanna (France)  
Laurence Moureau Zabotto (France)  
Patricia Niccoli (France)  
Flora Poizat (France)  
Olivier Turrini (France)

##### FACULTY

Philippe Bachellier (France)  
Marc Barthet (France)  
Cecile Braticevic (France)  
Marco J. Bruno (Netherlands)  
Thierry Conroy (France)  
Jérôme Cros (France)  
Jacques Deviere (Belgium)  
Nelson Dusetti (France)  
Thilo Hackert (Germany)  
Pascal Hammel (France)  
Florence Huguet (France)

Simon Launay (France)  
Ugo Marchese (France)  
Remy Nicolle (France)  
Jean Luc Raoul (France)  
Jean Philippe Ratone (France)  
Isabelle Rossi (France)  
Salvatore Paiella (Italy)  
Roberto Salvia (Italy)  
Alain Sauvanet (France)  
Florence Tenenbaum (France)



[www.pchm2020.com](http://www.pchm2020.com)



GENERAL ORGANISATION : MCO Congrès +33(0) 4 95 09 38 00 / [contact@mcocongres.com](mailto:contact@mcocongres.com)

# PANCREATIC CANCER HIGHLIGHTS MARSEILLE, FIGHT CANCER

LE PHARO | MARSEILLE FRANCE  
2020 JANUARY 16-17



INSTITUT PAOLI-CALMETTES  
tuncancer Marseille

## EDITO

---

This will be the second international event on pancreatic cancer in Marseille. Pancreatic cancer is the 12<sup>th</sup> most commonly occurring cancer in men and the 11<sup>th</sup> most commonly occurring cancer in women. Pancreatic cancer has the lowest survival of all cancers in Europe. Responsible for over 95,000 EU deaths every year, the median survival time at the point of diagnosis is just 4.6 months, with patients losing 98% of their healthy life expectancy. Often referred to as 'the silent killer', symptoms can be hard to identify, thus making it difficult to diagnose the disease early which is essential for life-saving surgery.

There were 460,000 new cases in 2018.

We have selected topics that translational and clinical pancreatic cancer research and therapy, including sessions on diagnostics, screening and therapy that have the potential to directly impact survival rates. Other topics that will be presented include genetic testing, immunology and immunotherapy, management of local disease, metabolism and metabolomics, precision medicine, signaling and oncogenes, and the tumor microenvironment. This meeting should be interactive with the participants, sessions as "meet the experts" and poster presentations are scheduled.

The organisation committee

# PANCREATIC CANCER

## HIGHLIGHTS MARSEILLE, FIGHT CANCER

LE PHARO | MARSEILLE FRANCE  
2020 JANUARY 16-17



INSTITUT PAOLI-CALMETTES  
Pancreatic Cancer Marseille

AN EVENT BY PAOLI-CALMETTES INSTITUTE

THURSDAY, JANUARY 16<sup>th</sup>

8.00-8.25 ○ **WELCOME**

8.25-8.30 ○ **OPENING:** P. Viens (Marseille)

8.30-9.30 ○ **SESSION 1 SCREENING & EARLY DIAGNOSIS**

Moderators: **JR. Delpero** (Marseille), **J. Iovanna** (Marseille),  
**F. Poizat** (Marseille)

- Pancreatic cancer screening: dream or nightmare: **M. Bruno** (Rotterdam)
- Molecular type and therapeutic impact: **J. Cros** (Paris)
- BRCA Patients Transferred: What Support in 2020? **P. Hammel** (Paris)

9.30-13.00 ○ **SESSION 2 CLINICAL PRACTICE**

Moderators: **M. Giovannini** (Marseille), **M. Arvanitaki** (Belgium),  
**O. Turrini** (Marseille)

● **Pro/Cons: Germany versus Italy on IPMN Management**

- Germany: **T. Hackert** (Heidelberg)
- Italy: **R. Salvia** (Verona)
- Discussion 10 mn

10.15-10.45 ○ **COFFEE BREAK novocure™**

● **How to “prepare” a patient with an operable pancreatic adenocarcinoma?**

Moderators: **T. Hackert** (Heidelberg), **R. Salvia** (Verona),  
**A. Sauvanet** (Paris)

- Neoadjuvant RadioChemotherapy: **F. Huguet** (Paris)
- Neoadjuvant Chemotherapy: **M. Gilabert** (Marseille)
- Is a preoperative EUS-FNA needed: **M. Bruno** (Rotterdam)
- Is a preoperative biliary Drainage needed: **M. Arvanitaki** (Belgium)
- Is a preoperative intensive nutrition needed: **C. Banner Braticevic** (Marseille)

● **Locally advanced pancreatic adenocarcinoma**

Moderators: **T. Hackert** (Heidelberg), **R. Salvia** (Verona),  
**JR. Delpero** (Marseille)

- What are the Limits of Surgery? **P. Bachellier** (Strasbourg)

# PANCREATIC CANCER

## HIGHLIGHTS MARSEILLE, FIGHT CANCER

LE PHARO | MARSEILLE FRANCE  
2020 JANUARY 16-17



INSTITUT PAOLI-CALMETTES  
un-cancer Marseille

AN EVENT BY PAOLI-CALMETTES INSTITUTE

### Do we need Expert Centers to increase the survival?

Moderators: **T. Hackert** (Heidelberg), **R. Salvia** (Verona),  
**JR. Delpero** (Marseille)

- Surgical point of view: **R. Salvia** (Verona)
- Gastroenterologist point of view: **M. Arvanitaki** (Belgium)
- Discussion

13.00-14.00 ○ LUNCH erytech 

14.00-15.30 ○ SESSION 3 LOCAL THERAPIES

Moderators: **M. Barthet** (Marseille), **O. Turrini** (Marseille),  
**M. Gilabert** (Marseille)

#### Tumor Ablation

- EUS guided Ablation: **M. Giovannini** (Marseille)
- Surgical Local Ablation: **S. Paiella** (Verona)
- Discussion

#### Ampullectomy

- Surgical ampullectomy: **A. Sauvanet** (Paris)
- Endoscopic ampullectomy: **M. Barthet** (Marseille)
- Discussion

15.30-16.00 ○ COFFEE BREAK novocure™

16.00-17.30 ○ SESSION 4 CONFERENCES

- What we learn of pacaomics study: **N. Dusetti** (Marseille)
- Folfirinox in pancreatic adenocarcinoma: **T. Conroy** (Nancy)
- Mechanisms of tumor resistance: **J. Iovanna** (Marseille)
- History of pancreatic surgery: **JR. Delpero** (Marseille)

17.30-18.30 ○ COCKTAIL novocure™

# PANCREATIC CANCER

## HIGHLIGHTS MARSEILLE, FIGHT CANCER

LE PHARO | MARSEILLE FRANCE  
2020 JANUARY 16-17



INSTITUT PAOLI-CALMETTES  
un-cancer Marseille

AN EVENT BY PAOLI-CALMETTES INSTITUTE

FRIDAY, JANUARY 17<sup>th</sup>

8.30-8.45 ○ WELCOME

8.45-10.00 ○ SESSION 5 RADIOTHERAPY & CHEMOTHERAPY

Moderators: **JL. Raoul** (Nantes), **M. Gilabert** (Marseille),  
**L. Moureau-Zabotto** (Marseille)

- Is the Radiotherapy less used in Europe?: **F. Huguet** (Paris)
- Metastatic Pancreatic Adenocarcinoma: a black hole for systemic therapies: **JL. Raoul** (Nantes)
- "A la Carte" Therapies: **R. Nicolle** (Paris)

10.00-10.40 ○ SESSION 6 PANCREATIC ADENOCARCINOMA:  
WHAT'S NEW ?

Moderators: **JL. Raoul** (Nantes), **M. Gilabert** (Marseille),  
**JR Delpero** (Marseille)

- Endoscopy: **JP. Ratone** (Marseille)
- Surgery: **U. Marchese** (Marseille)
- Radiotherapy: **L. Moureau-Zabotto** (Marseille)
- Chemotherapy: **B. Chanez** (Marseille)

10.40-11.00 ○ COFFEE BREAK erytech 

11.00-12.00 ○ SESSION 7 PANCREATIC NEURO-ENDOCRINE  
TUMORS

Moderators: **JL. Raoul** (Nantes), **I. Rossi** (Marseille),  
**P. Niccoli** (Marseille)

- PET GALLIUM & PNET: **F. Tenenbaum** (Paris)
- Systemic Therapies: **P. Niccoli** (Marseille)

12.00 ● Closing Remarks: **M.Giovannini** & **O.Turrini**

# PANCREATIC CANCER

## HIGHLIGHTS MARSEILLE, FIGHT CANCER

LE PHARO | MARSEILLE FRANCE  
2020 JANUARY 16-17



INSTITUT PAOLI-CALMETTES  
un cancer Marseille

SILVER SPONSOR

**novocure™**

BRONZE SPONSOR

**erytech**

SPONSORS



INSTITUTIONAL PARTNER



With the support of





# POSTERS

---

- P001** Autoantigen Biomarkers for the Pre-symptomatic Diagnosis of Pancreatic Ductal Adenocarcinoma. **Metoborghene Mowoe**
- P002** Contribution to the molecular study of pancreatic cancer: study of the association between C677T polymorphism of the MTHFR gene and the occurrence of pancreatic cancer. **Meriem Abdi**
- P003** Isolation of cancer stem cells in metastatic pancreatic ductal adenocarcinoma. **Nona Merckx**
- P004** PANOVA-3: A phase 3 study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC). **Teresa Macarulla**
- P005** EGFR and COX2 protein overexpression in Pakistani pancreatic cancer patients. **Yumna Adnan**
- P006** Role of cancer stem cell markers in pancreatic adenocarcinoma patients of Pakistan. **S. M. Adnan Ali**

# NOTES

---

A series of horizontal dotted lines for writing notes.



# NOTES

---

A series of horizontal dotted lines for writing notes.

# NOTES

---

A series of horizontal dotted lines for writing notes.

# 1<sup>er</sup> Couple Théranostique Approuvé dans les TNE-GEP\*



Diagnostic

Thérapie

## SomaKIT TOC® 40 µg (édotréotide)

Trousse pour préparation radiopharmaceutique

### Détecte ce qui pourrait échapper à d'autres

Une nouvelle ère dans la prise en charge des  
TNE-GEP pour une prise en charge optimisée.<sup>1</sup>

SomaKIT TOC® 40 µg (édotréotide) est à usage diagnostique uniquement.

Après radiomarquage avec la solution de chlorure de gallium (<sup>68</sup>Ga), la solution de gallium (<sup>68</sup>Ga) édotréotide obtenue est indiquée pour l'imagerie par tomographie par émission de positons (TEP) de la surexpression de récepteurs de la somatostatine afin de localiser les tumeurs primitives et leurs métastases chez des patients adultes atteints de tumeurs neuroendocrines gastro-entéro-pancréatiques (TNE-GEP) bien différenciées confirmées ou suspectées<sup>2</sup>.

La TEP après administration de SomaKIT TOC est un examen de 1<sup>ère</sup> intention dans le diagnostic des tumeurs endocrines gastroentéro-pancréatiques suspectées ou connues dans le cadre du bilan initial (bilan d'extension)<sup>3</sup>.

<sup>1</sup> Frilling A et al. The impact of <sup>68</sup>Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010;252(5):850-6.

<sup>2</sup> Résumé des Caractéristiques du Produit - SomaKIT TOC®

<sup>3</sup> Avis de la Commission de la Transparence du 19 Juillet 2017 - SomaKIT TOC®

## LUTATHERA® (lutécium (<sup>177</sup>Lu) oxodotréotide)

370 MBq/mL - Solution pour perfusion

### Chasseur de tumeurs

LUTATHERA® (lutécium (<sup>177</sup>Lu) oxodotréotide) 370 MBq/mL est indiqué pour le traitement des tumeurs neuroendocrines gastroentéropancréatiques (TNE-GEP) inopérables ou métastatiques, progressives, bien différenciées (G1 et G2) et exprimant des récepteurs de somatostatine chez les adultes<sup>1</sup>.

<sup>1</sup> Résumé des Caractéristiques du Produit - LUTATHERA®

\* TNE-GEP : Tumeurs NeuroEndocrines GastroEntéroPancréatiques.



Avant de prescrire, consultez la place dans la stratégie thérapeutique sur [www.has-sante.fr](http://www.has-sante.fr)

Les mentions obligatoires sont accessibles sur la base de données publique des médicaments. <http://base-donnees-publique.medicaments.gouv.fr>

▼ Ces médicaments font l'objet d'une surveillance supplémentaire qui permettra l'identification rapide de nouvelles informations relatives à la sécurité.



## **A NEW STUDY FOR** PANCREATIC CANCER PATIENTS USING TTFields

Novocure is conducting a global, pivotal randomized controlled trial, designed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel as front-line treatment for patients with locally advanced pancreatic adenocarcinoma that is not amenable to surgical resection.

This medical device delivers Tumor Treating Fields (TTFields) to the abdominal region where the tumor is located. The NovoTTF 100L(P) System is not FDA approved or CE marked in Europe to treat pancreatic cancer. Therefore, the safety and efficacy of TTFields in this condition is still unknown, and will be evaluated in this study.

If you are interested in participating in our clinical research study, or have questions regarding PANOVA-3, please contact our team at **[BForizs@novocure.com](mailto:BForizs@novocure.com)**

Learn more about the PANOVA-3 study at:  
**[novocuretrial.com/panova](http://novocuretrial.com/panova)**



**novocure™**